Ex Vivo Adenovirus-Mediated Gene Transfer To The Adult Rat Heart  by Kypson, Alan P. et al.
CARDIAC AND PULMONARY
REPLACEMENT
EX VIVO ADENOVIRUS-MEDIATED GENE TRANSFER TO THE ADULT RAT HEART
Alan P. Kypson, MDa
Karsten Peppel, PhDb
Shahab A. Akhter, MDa
R. Eric Lilly, MDa
Donald D. Glower, MDa
Robert J. Lefkowitz, MDb,c
Walter J. Koch, PhDa
Sponsor:
Robert W. Anderson, MDa
Objective: The ability to transfer genes to adult myocardium may have
therapeutic implications for cardiac transplantation. We investigated the
feasibility of adenovirus-mediated transfer of marker genes LacZ and Lucif-
erase, as well as the potentially therapeutic gene of the human b2-adrenergic
receptor in a rat heterotopic heart transplant model. Methods: Donor hearts
were flushed with 1012 total viral particles of one of three transgenes. Hearts
were harvested at various time points after transplantation. LacZ-treated
hearts were assessed by histologic staining and Luciferase-treated hearts were
assayed for specific luminescence activity. Hearts treated with b2-adrenergic
receptor underwent radioligand binding assays and immunohistochemistry
with the use of an antibody specific for the human b2-adrenergic receptor.
Results: LacZ hearts revealed diffuse myocyte staining as opposed to none
within controls at 5 days. Luciferase hearts demonstrated a mean activity of
970,000 6 220,000 arbitrary light units versus 500 6 200 for the controls (p 5
0.001). Total b2-adrenergic receptor densities (fmol/mg membrane protein) for
hearts that received the b2-adrenergic receptor transgene at 3, 5, 7, 10, and 14
days after infection were as follows: right ventricle, 488.5 6 126.8, 519.4 6
81.8,* 477.1 6 51.8,* 183.0 6 6.5,* and 82.7 6 19.1; left ventricle, 511.0 6 167.6,
1206.4 6 321.8,* 525.3 6 188.7, 183.5 6 18.6,* and 75.9 6 15.2 (*p < 0.05 vs
control value of 75.6 6 6.4). Immunohistochemical analysis revealed diffuse
staining of varying intensity within myocardial sarcolemmal membranes.
Conclusions: We conclude that global overexpression of different transgenes is
possible during cardiac transplantation and, ultimately, adenovirus-mediated
gene transfer may provide a unique opportunity for genetic manipulation of
the donor organ, potentially enhancing its function. (J Thorac Cardiovasc Surg
1998;115:623-30)
Cardiac gene transfer refers to the alteration ofthe genetic content of cells within the heart.
Typically this is facilitated by the vector-mediated
addition of a foreign gene. The further development
of such technology might allow novel therapeutic
approaches in the treatment of cardiovascular dis-
eases. However, lack of effective and clinically ap-
plicable gene delivery systems resulting in high
levels of transgene overexpression has been a major
obstacle for successful cardiac gene transfer. To
date, the adenovirus has proved to be a fairly
reliable vector for cardiac gene transfer, because it
has the characteristic of being able to infect nondi-
viding cells, which is an absolute requirement for the
terminally differentiated myocyte. Direct injection
of plasmid deoxyribonucleic acid (DNA) results in
localized gene delivery and is not clinically applica-
ble.1-4 Percutaneous in vivo delivery systems, such as
coronary artery catheterization in rabbits5, 6 and
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dogs,7, 8 have had variable success, are difficult to
reproduce, and infect a limited region of the heart.
Ex vivo delivery systems, such as during cardiac
transplantation, are clinically relevant and have
been shown to allow gene transfer by several differ-
ent vectors.9-13
The application of gene transfer to cardiac trans-
plantation is especially appealing because of the
direct access to the donor organ at the time of
harvest. One could potentially transfer the foreign
genetic material at that time, and expression of the
transgene could be evident within 12 to 24 hours.
This has been demonstrated in mice, rats, and
rabbits.9-13 Most of these reports however, have
focused on the use and overexpression of a marker
gene. Because of differences in individual transgene
factors such as transgene immunogenicity, the ex-
pression of one transgene does not necessarily cor-
relate to the expression of others. Thus in this report
we attempted to deliver three different transgenes to
the myocardium, including the human b2-adrenergic
receptor (b2-AR). If myocardium-targeted overex-
pression of b2-AR occurs, cardiac function might be
enhanced, as has been shown in transgenic mice.14
Materials and methods
Construction of recombinant adenovirus. Construction
of the cytoplasmic b-galactosidase expressing adenovirus
(Ad.LacZ) has been described elsewhere.15 The Lucif-
erase expressing adenovirus (Ad.Luc) was a kind gift from
Dr. R. Gerard (University of Texas, Southwestern Medi-
cal Center). Construction of the human b2-adrenergic
receptor (Ad.b2-AR), cell culture conditions, and virus
preparation have been described in detail elsewhere.16
Animals. All procedures and protocols were approved
by the Animal Care and Use Committee of Duke Univer-
sity. Adult male Long Evans rats (250 to 300 gm),
obtained from Harlan Sprague Dawley, Inc. (Indianapolis,
Ind.) were housed under standard conditions and fed a
standard diet and water. All animals received humane
care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for
Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Labo-
ratory Animal Resources and published by the National
Institutes of Health (NIH publication No. 85-23, revised
1985).
Heterotopic heart transplantation. Heterotopic intra-
abdominal heart transplantation was performed using the
technique as previously described by Ono and Lindsey.17
In brief, both donor and recipient underwent anesthesia
with a mixture of ketamine (50 mg/kg) and xylazine (5
mg/kg) injected intraperitoneally. The donor was hepa-
rinized. A clamshell incision was created to expose the
thoracic organs. Donor hearts were arrested with 5 ml of
normothermic Roe’s cardioplegic solution (20 mEq KCl,
27 mEq NaCl, 3 mEq MgSO4, 250 mg methylprednisolone
sodium succinate, and 2.25 mEq NaHCO3 for a pH of
7.4). Cardiectomy was performed and 1 ml of adenoviral
solution (1012 total viral particles) was rapidly injected
into the aortic root.
At this point, attention was turned to the recipient. The
infrarenal aorta and vena cava were exposed via a midline
abdominal incision. An end-to-side anastomosis was per-
formed between the donor and recipient aorta followed by
an end-to-side anastomosis of the donor pulmonary artery
to the recipient vena cava. Bleeding was controlled with
direct pressure. All hearts resumed normal sinus rhythm
within 5 minutes. Total ischemic time was between 30 and
50 minutes. During transplantation, the heart was
wrapped in gauze and kept at approximately 4° C through
use of topical iced saline solution, although myocardial
temperature was not measured. After completion of each
procedure, the rats recovered under a heat lamp. They
were then returned to their cages and allowed free access
to food and water. Abdomens were palpated daily to
assure a functioning graft.
Experimental design. To assess gene transfer of the
marker gene LacZ, we gave one group of rats (n 5 6) the
Ad.LacZ solution and another group (n 5 6) the control
solution containing an adenovirus that does not express a
transgene (Ad.MT). Both groups of rats were put to death
5 days after transplantation. To assess successful transfer
of the Luciferase marker gene, we injected one group of
rats (n 5 6) with Ad.Luc and the control group (n 5 6)
with Ad.MT. Both groups were put to death 5 days after
transplantation. To determine gene transfer of the b2-AR,
one group (n 5 6) received Ad.b2-AR and the controls
(n 5 6) received Ad.MT. Both of these groups were put to
death 5 days after transplantation and all hearts were
divided into three samples: (1) left and right atria, (2)
right ventricle, and (3) left ventricle. Furthermore, groups
of three rats each were then infected with Ad.b2-AR and
put to death 3, 5, 7, 10, and 14 days after transplantation.
Likewise, all hearts were divided into the previously
described three samples.
b-Galactosidase staining. Hearts were excised, rinsed
in isotonic saline solution, frozen in a dry ice/isopentane
solution, and stored at –80° C. Specimens were mounted
on a freezing microtome and 10 mm sections were trans-
ferred to glass slides pretreated with aminoalkylsilane
(Sigma Chemical Company, St. Louis, Mo.). Sections
were fixed in 10% formalin for 2 minutes at room
temperature and washed twice in isotonic saline solution.
b-Galactosidase staining was carried out in 2 mmol/L
K4Fe(CN)6, 2 mmol/L K3Fe(CN)6, 2 mmol/L MgCl2, 0.5
mg/ml X-gal (5-bromo-4-chloro-3-indoyl-b-D-galactopyr-
anoside) in tromethamine-buffered saline solution, pH
7.4. After being stained (usually 30 minutes to 2 hours),
the sections were rinsed in tromethamine-buffered saline
solution and counterstained with eosin.
Luciferase assays. Hearts were excised, rinsed in iso-
tonic saline solution, and weighed. One milliliter per gram
of tissue of 5 mmol/L tromethamine/HCl (pH 7.4), 132
mmol/L NaCl, and 0.5 mmol/L of ethylenediaminetet-
raacetic acid (EDTA) was added. Specimens were homog-
enized with a Polytron homogenizer (Brinkman Instru-
ments, Westbury, N.Y.) and flash-frozen in liquid
nitrogen. After one freeze/thaw cycle, the homogenate
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was centrifuged at 10,000g for 2 minutes and the super-
natant was saved and assayed for Luciferase activity ac-
cording to the manufacturer’s instructions (Promega
Corp., Madison, Wis.). In brief, in a 1.5 ml screw-cap
Eppendorf tube (Sarsted, Inc., Newton, N.C.), 2 ml of the
extract was added to 18 ml of 1x reporter lysis buffer
(Promega). Twenty microliters of reconstituted Luciferase
assay substrate (Promega) was added and incubated for 2
minutes at room temperature. Photon production was
then measured in a scintillation counter in single photon
counting mode (Beckman Instruments, Inc., Fullerton,
Calif.).
b-AR binding assays. Membrane fractions were pre-
pared from hearts and resuspended in binding buffer (75
mmol/L tromethamine-HCl, pH 7.4/12.5 mmol/L MgCl2/2
mmol/L EDTA). Binding assays were performed on 25 mg
of membrane protein using saturating amounts of the
b-AR–specific ligand [–125I]cyanopindolol (300 pmol/L).
Nonspecific binding was determined in the presence of 20
mmol/L alprenolol. Reactions were conducted in 500 ml of
binding buffer at 37° C for 1 hour and terminated by
vacuum filtration through glass-fiber filters. b1 and b2
subtype proportions were determined by competition with
varying doses of the b2-selective ligand ICI 118,551. All
Fig. 1. A, Cross section of a rat heart taken at the mid-ventricular level (2.53 magnification) 5 days after
Ad.LacZ infection. B, Same view at higher magnification (1003). Notice individual myocyte staining.
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assays were performed in triplicate, and receptor density
(fmol) was normalized to milligrams of membrane pro-
tein.
Immunohistochemical labeling. Frozen sections were
cut at 10 mm for indirect immunofluorescence studies.
Sections were rinsed three times for 3 minutes in phos-
phate-buffered saline solution (PBS) and 3 minutes in
PBS with 0.05% octyphenoxy polyethoxyethanol (Triton
X-100; Union Carbide Corp., Danbury, Conn.) (Triton-
PBS), blocked with serum diluent (10% goat serum in
PBS with 0.1% bovine serum albumin and 0.1% sodium
azide), and then rinsed for 15 minutes in Triton-PBS
before overnight incubation at 4° C with a primary rabbit
antihuman b2-AR antiserum
18 (1:500 dilution in serum
diluent). The sections were then washed four times for 10
minutes in Triton-PBS at room temperature and incu-
bated for 1 hour in fluorescein isothiocyanate–conjugated
goat antirabbit immunoglobulin G (1:50 dilution in serum
diluent). After five 3-minute rinses in PBS, the sections
were mounted with sodium iodide (25 gm/L) in 1:1
PBS/glycerol solution and photographed.
Statistical analysis. Quantitative data such as myocar-
dial Luciferase activity and b-AR density after adenoviral
transgene delivery is expressed as the mean 6 standard
error of the mean. The difference in the level of transgene
expression between control and infected hearts was eval-
uated with Student’s t test.
Results
Survival. Approximately 10% of all rats that un-
derwent transplantation died within 24 hours of the
operation. Deaths were equally distributed among
the groups. No animals died if they survived the first
24 hours after transplantation. All hearts were in
normal sinus rhythm at time of explantation. Histo-
logic examination revealed no abnormalities and
differences between the experimental and control
groups at all the various times when the animals
were put to death.
LacZ overexpression. All hearts that underwent
infection with Ad.LacZ demonstrated diffuse stain-
ing throughout both ventricles, as well as both atria.
Staining was nonuniform and myocytes staining blue
were found throughout the various layers of the
myocardium, with little evidence of endothelial cell
infection (Fig. 1). None of the control hearts stained
positive for b-galactosidase.
Luciferase overexpression. All hearts that under-
went infection with Ad.Luc demonstrated significant
overexpression (970,000 6 220,000 arbitrary light
units) as compared with the controls (500 6 200
arbitrary light units; p 5 0.001). Because whole
hearts were homogenized for this assay, determina-
tion of the distribution of this transgene was not
studied.
Human b2-AR time course of overexpression.
Hearts injected with Ad.b2-AR revealed marked
overexpression in both the right and left ventricles
as compared with the control hearts (Fig. 2). This
represents an approximate sixfold increase in the
right ventricle and fourteenfold increase in the
left ventricle. The fraction of b2-ARs increased to
90% in the left ventricle from a fraction of 30% in
the control hearts, demonstrating that the in-
creased b-AR density was due exclusively to
b2-AR overexpression. Furthermore, immunohis-
tochemical analysis for the human b2-AR re-
vealed several areas of diffuse staining of myocar-
dial sarcolemmal membranes of various
intensities (Fig. 3).
In rats put to death 3 to 14 days after transplan-
tation, peak overexpression occurred at 5 days, and
b-AR density was back to control values by 14 days,
although at 10 days overexpression was still signifi-
cant. The atria exhibited the same temporal pattern
of overexpression as the left ventricle, whereas
overexpression in the right ventricle peaked at 3
days and remained at that level for the first 7 days
before returning to control values by postoperative
day 14 (Fig. 4).
Discussion
The milieu of the heart during transplantation is
an ideal situation for the introduction of foreign
genetic material into cardiac myocytes. Gene trans-
fer to the donor organ, at the time of harvest, can
easily be accomplished with an adenoviral vector.
The role of gene transfer for the treatment of
cardiac disorders is evolving and may potentially
Fig. 2. b-AR density in native recipient hearts (n 5 6),
control transplanted hearts after Ad.LacZ delivery (n 5
6), and in b2-AR-treated hearts (n 5 6) 5 days after
transplantation. *p , 0.02 versus controls.
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include applications for the treatment of congestive
heart failure, transplant rejection and dysfunction,
and ischemic heart disease. However, it remains to
be seen whether different transgenes that would be
required to treat these disorders can be directed to
and overexpressed in the human myocardium under
the conditions of current technology.
Recently, the adenovirus vector has been shown
to have increased efficacy of gene transfer into cells
both in vivo and in vitro.6, 11, 12, 16 Recombinant
adenoviral vectors have a number of advantages
over other viral and nonviral vectors. Adenoviral
vectors provide efficient transfer into cells that are
terminally differentiated. They can be made replica-
tion deficient, can be produced in high titer, and can
carry up to 7.5 kb of exogenous genetic material.19
Therefore this study took advantage of these char-
acteristics to test delivery of three different trans-
genes, one with a potential future application of
improving myocardial contractility.
The present study demonstrates that the time of
cardiac transplantation is an ideal setting for the
administration of an adenoviral solution to “genet-
ically modulate” the organ. Several reports have
shown that the expression of reporter genes directly
injected into the myocardium is limited to a finite
area around the site of injection and is further
complicated by local inflammation.1, 3 Therefore
this raises doubts about the clinical applicability of
this method of gene delivery. In vivo intracoronary
Fig. 3. Representative immunohistochemical detection of expressed human b2-ARs 5 days after
Ad.b2-AR delivery to transplanted rat hearts. A, Cross-sectioned myocytes at 253 magnification. B,
Longitudinally sectioned myocytes at 1003 magnification.
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delivery has been demonstrated,5, 6 but it is very
difficult to reproduce consistently, probably because
of insufficient contact time between the adenovirus
and the beating myocardium, as well as a host of
other reasons that have yet to be identified.
Unlike direct injection, infection through the cor-
onary vasculature during cardiac transplantation
results in robust and widespread overexpression of
the transgene, as evidenced by the extensive b-ga-
lactosidase staining of the right and left ventricles on
histologic examination, as well as the marked over-
expression of the b2-AR, not only in both ventricles,
but in both atria as well. The transplantation model
is unique in that it provides the mechanism to
accomplish global myocardial gene transfer. First,
adenoviral solution is injected into the aortic root,
presumably via both right and left coronary arteries,
providing access to the entire myocardium. The
solution is delivered immediately after removal of
the heart at normothermia. No hypothermia is used
in this model because this may reduce the efficacy of
gene transfer by slowing the kinetics of the virus-
receptor interaction. In fact, we have observed lower
amounts of adenoviral gene transfer with hypother-
mia (data not shown). Furthermore, donor heart
ischemia may facilitate viral transfection by making
the endothelium more permeable. This, combined
with the fact that the adenoviral solution is in
constant contact with the myocardium throughout
the procedure, likely further enhances gene transfer
across the endothelium and into the myocardium
itself. This constant exposure probably saturates the
viral receptors and must partially account for the
robust overexpression of transgenes seen in this
model. As opposed to other reports,9, 11, 13 we have
not observed any significant expression in endothe-
lial cells within the vasculature of the heart, but
extensive gene transfer to myocytes was evidenced
by the histologic pattern of LacZ staining, as well as
the pattern of b2-AR overexpression detected by
immunohistochemistry. The lack of endothelial ex-
pression was surprising, and further studies will be
required to shed more light on the mechanism of
myocyte/endothelial cell gene transfer in our model.
Ultimately, however, enhancement of cardiac func-
tion through b-AR overexpression requires target-
ing myocytes rather than endothelial cells, which has
been achieved in this report.
The analysis of the time course of gene expression
in our model correlates fairly closely with other
reports.11, 12 Peak b2-AR overexpression was
reached at 5 days, and by 14 days expression was
back to control values. However, we have no expla-
nation for the apparent difference in the kinetics of
transgene expression in the right ventricle (Fig. 4).
More recently, we have looked at expression at 28
Fig. 4. Time course of overexpression at 3, 5, 7, 10, and 14 days of b-ARs in atria, right ventricle (RV), and
left ventricle (LV) after delivery of 1012 total viral particles of Ad.b2-AR (n 5 3 per time point). *p , 0.05
compared with b-AR density of control native hearts (75.6 6 6.4).
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days and have found no evidence of significant
overexpression. Some reports20 describe stable gene
expression up to months, but these are in different
animal models with different delivery systems.
Clearly, further work will have to be done to in-
crease the stability of these transgenes. Probable
advances will come in work done on the adenovirus
itself by further deleting immunogenic regions, in
essence “hiding” the adenovirus from the host’s
immune system. An immune response to adenovirus
has been reported1, 21 and may be partly responsible
for the transient overexpression seen with this
model. Of note, immunosuppressive therapies have
been shown to greatly extend the duration of trans-
gene expression mediated by recombinant replica-
tion-deficient adenovirus.22, 23 Although we have
not yet examined the role of immunosuppression in
our model, it is possible that the immunosuppressive
regimen used currently in the cardiac posttransplant
setting might allow for extended transgene expres-
sion mediated by these viruses. However, this may
also prove to make the recipient more vulnerable to
potential adenoviral infections using the current
vectors. The creation of advanced gene transfer
vectors, which is the focus of several groups, should
eventually eliminate this possibility. Importantly,
in our model, there was no histologic evidence in
the transplanted rat hearts of any direct injury
caused by the adenovirus out to 28 days after
transplantation.
In conclusion, we have shown that ex vivo adeno-
virus-mediated gene transfer is possible in the adult
rat heterotopic heart transplant model. Not only
have we demonstrated successful gene transfer of
two marker genes, but we have also demonstrated
for the first time robust and global overexpression of
a gene encoding for an endogenous membrane
protein (b2-AR), which has been shown to increase
myocardial contractility in transgenic mice.14 Thus,
in future studies, it will be critical to document the
functional significance of b2-AR overexpression in
this model to determine whether genetic modifica-
tion can be successful at improving myocardial
function in the posttransplantation setting.
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Discussion
Mr. Magdi H. Yacoub (London, United Kingdom). Have
you looked at the effect of overexpression of b-receptors
on function of these cells in any way, either in vitro or in
any other way?
Dr. Alan P. Kypson (Durham, N.C.). Yes, we have just
started our preliminary studies.
We transfected six hearts with the b2-receptor and
showed overexpression. (Average b-receptor density was
400 fmol as compared our controls [80 fmol]). These same
rat hearts were then mounted on a Langendorff apparatus
5 days after infection and there was almost a doubling of
the baseline rate of pressure rise in these infected hearts
as compared with the control hearts. We have yet to do
b-agonist dose/response curves as well as evaluate the
amount of overexpression correlating with the functional
effect. These are very preliminary data, but there does
seem to be some sort of a functional enhancement.
Dr. Tirone E. David (Toronto, Ontario, Canada). These
measurements are done at what stage of the experiment?
Dr. Kypson. At 5 days we remove the heart from the
abdomen and perfuse it on a Langendorff apparatus.
Dr. David. Did you do any after 14 days?
Dr. Kypson. No. We have looked only at 5 days so far.
Mr. John H. Kennedy (Cambridge, United Kingdom). Is
the life of the transfected cells shorter than the life of the
host or longer? They are obviously better.
Dr. Kypson. There are some who believe that the cells
that overexpress these transgenes undergo an immune
response by the host. We have looked at the pathology of
these hearts 28 days after transplantation and have seen
normal histologic characteristics.
Dr. D. Glenn Pennington (Winston-Salem, N.C.). Is
there a real difference in the right and the left ventricles,
or is that just a matter of muscle mass?
Dr. Kypson. Actually, this probably relates to some sort
of an increased transmural pressure wall gradient gener-
ated in the left ventricle, which enhances transduction of
the viral particles across the endothelium into the myo-
cardium.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
6 3 0 Kypson et al.
